Zurex Pharma, a pharma and medical technology company with a novel antimicrobial technology platform, raised $9 million in advance of a pending new drug application (NDA) submission, the company announced recently.

According to a release, the round was led by the company’s current shareholders, and a portion of the funding was comprised of debt financing by Square 1 Bank.

The money will be used to support Zurex’s pending NDA submission and review by the U.S. Food and Drug Administration for sales and marketing approval of ZurexPrep, a pre-surgical skin preparation product.

“We are very excited about the near-term NDA submission for our first product, ZurexPrep,” Zurex Pharma CEO Carmine Durham said in a statement. “Our team is grateful for our strong and supportive investor base and glad to have Square 1 on board as our financial services partner.”